Ana Custodio

2.3k total citations
75 papers, 1.2k citations indexed

About

Ana Custodio is a scholar working on Oncology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ana Custodio has authored 75 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 33 papers in Epidemiology and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ana Custodio's work include Neuroendocrine Tumor Research Advances (31 papers), Lung Cancer Research Studies (29 papers) and Neuroblastoma Research and Treatments (15 papers). Ana Custodio is often cited by papers focused on Neuroendocrine Tumor Research Advances (31 papers), Lung Cancer Research Studies (29 papers) and Neuroblastoma Research and Treatments (15 papers). Ana Custodio collaborates with scholars based in Spain, United Kingdom and Italy. Ana Custodio's co-authors include Jaime Feliú, Míriam Méndez, Mariano Provencio, Rocio García‐Carbonero, Virginia Martínez-Marín, Eduardo Díaz‐Rubio, Enrique Grande, Paula Jiménez‐Fonseca, Jaume Capdevila and Àlex Teulé and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ana Custodio

73 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ana Custodio Spain	21	705	334	306	301	246	75	1.2k
Teresa Alonso‐Gordoa Spain	19	619 0.9×	333 1.0×	343 1.1×	366 1.2×	253 1.0×	82	1.2k
Ferdinando Riccardi Italy	18	602 0.9×	283 0.8×	296 1.0×	190 0.6×	108 0.4×	77	875
Javier Molina‐Cerrillo Spain	17	384 0.5×	137 0.4×	303 1.0×	342 1.1×	87 0.4×	66	967
Jian Feng China	22	477 0.7×	184 0.6×	457 1.5×	491 1.6×	187 0.8×	85	1.4k
Céline Lepère France	15	1.3k 1.8×	433 1.3×	477 1.6×	147 0.5×	169 0.7×	43	1.6k
Raffaele Costanzo Italy	16	563 0.8×	194 0.6×	368 1.2×	277 0.9×	54 0.2×	53	899
Venessa Tsang Australia	21	600 0.9×	322 1.0×	143 0.5×	211 0.7×	130 0.5×	48	1.1k
Lauren K. Brais United States	17	902 1.3×	478 1.4×	99 0.3×	246 0.8×	271 1.1×	39	1.3k
Amy K. Kim United States	12	263 0.4×	140 0.4×	216 0.7×	269 0.9×	184 0.7×	28	976

Countries citing papers authored by Ana Custodio

Since Specialization

Citations

This map shows the geographic impact of Ana Custodio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Custodio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Custodio more than expected).

Fields of papers citing papers by Ana Custodio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Custodio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Custodio. The network helps show where Ana Custodio may publish in the future.

Co-authorship network of co-authors of Ana Custodio

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Custodio. A scholar is included among the top collaborators of Ana Custodio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Custodio. Ana Custodio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hernando, Jorge, Javier Molina‐Cerrillo, Rocio García‐Carbonero, et al.. (2025). Data from Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). DIGITAL.CSIC (Spanish National Research Council (CSIC)).

Hernando, Jorge, Javier Molina‐Cerrillo, Rocio García‐Carbonero, et al.. (2025). Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). Clinical Cancer Research. 31(22). 4655–4663.

Martínez, María Carmen Riesco, Jaume Capdevila, Vicente Alonso, et al.. (2024). Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913). Nature Communications. 15(1). 6753–6753. 10 indexed citations

Salvia, Anna La, Jaume Capdevila, Marta Benavent, et al.. (2023). Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival. European Journal of Endocrinology. 190(1). 62–74. 6 indexed citations

Viñal, D., et al.. (2023). Prognostic value of tumor budding in patients with stage II and III colon cancer: A single-institution experience.. Journal of Clinical Oncology. 41(4_suppl). 247–247. 1 indexed citations

Feliú, Jaime, Ana Custodio, Oliver Higuera, et al.. (2023). Predicting Risk of Severe Toxicity and Early Death in Older Adult Patients Treated with Chemotherapy. Cancers. 15(18). 4670–4670. 2 indexed citations

Grande, Enrique, Cristina Rodríguez‐Antona, Carlos López, et al.. (2021). Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial. The Oncologist. 26(11). 941–949. 16 indexed citations

Capdevila, Jaume, Àlex Teulé, Carlos López, et al.. (2020). 1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601). Annals of Oncology. 31. S770–S771. 37 indexed citations

Salvia, Anna La, Jaume Capdevila, Marta Benavent, et al.. (2020). 1159MO Survival and prognostic factors analysis of 535 grade 3 gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN): Data from the Spanish Taskforce of Neuroendocrine Tumours Registry (R-GETNE). Annals of Oncology. 31. S772–S772. 1 indexed citations

10.

Grande, Enrique, Àlex Teulé, Teresa Alonso‐Gordoa, et al.. (2020). The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). The Oncologist. 25(9). 745–e1265. 24 indexed citations

11.

Barriuso, Jorge, Ana Custodio, Vicente Alonso, et al.. (2018). Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. Cancer Treatment Reviews. 70. 209–222. 13 indexed citations

12.

Sundar, Raghav, Ana Custodio, Maxime Chénard-Poirier, et al.. (2017). Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. Clinical Oncology. 30(3). 185–191. 3 indexed citations

13.

Vargas, Teodoro, Juan Moreno‐Rubio, Jesús Herránz, et al.. (2016). 3’UTR Polymorphism in ACSL1 Gene Correlates with Expression Levels and Poor Clinical Outcome in Colon Cancer Patients. PLoS ONE. 11(12). e0168423–e0168423. 27 indexed citations

14.

Custodio, Ana, Juan Moreno‐Rubio, Jorge Aparicio, et al.. (2014). Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy. Molecular Cancer Therapeutics. 13(9). 2226–2237. 10 indexed citations

15.

Vargas, Teodoro, Juan Moreno‐Rubio, Jesús Herránz, et al.. (2014). Genes associated with metabolic syndrome predict disease‐free survival in stage II colorectal cancer patients. A novel link between metabolic dysregulation and colorectal cancer. Molecular Oncology. 8(8). 1469–1481. 26 indexed citations

16.

Cruzado, Juan Antonio, et al.. (2014). Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. Supportive Care in Cancer. 22(7). 1815–1823. 79 indexed citations

17.

González‐Vallinas, Margarita, Teodoro Vargas, Juan Moreno‐Rubio, et al.. (2014). Clinical relevance of the differential expression of the glycosyltransferase gene GCNT3 in colon cancer. European Journal of Cancer. 51(1). 1–8. 30 indexed citations

18.

Custodio, Ana, Juan Moreno‐Rubio, Jorge Aparicio, et al.. (2013). Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Annals of Oncology. 25(2). 398–403. 44 indexed citations

19.

Custodio, Ana & Javier de Castro. (2011). Strategies for maintenance therapy in advanced non-small cell lung cancer: Current status, unanswered questions and future directions. Critical Reviews in Oncology/Hematology. 82(3). 338–360. 15 indexed citations

20.

García-Sáenz, José Á., Miguel Martín, Antonio Calles, et al.. (2008). Bevacizumab in Combination with Metronomic Chemotherapy in Patients with Anthracycline- and Taxane-Refractory Breast Cancer. Journal of Chemotherapy. 20(5). 632–639. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact